Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMEYIVW)

Drug Name

CAP1-6D Drug Info

Synonyms

Modified CEA peptide (pancreatic cancer), University of Chicago

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Carcinoembryonic antigen CEA (CD66e)	DTT	CEACAM5	5.812	11.49	6.112	6.957

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Pancreatic cancer

ICD Disease Classification

2C10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Carcinoembryonic antigen CEA (CD66e)	DTT	CEACAM5	6.68E-91	0.29	1.07

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00203892) Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
2	Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.